BibTex RIS Cite

Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases

Year 2015, Volume: 5 Issue: 4, 151 - 155, 06.02.2016
https://doi.org/10.5799/ahinjs.02.2015.04.0196

Abstract

Objective: The combination of pegylated interferon-α (PEG-IFN) and ribavirin has become a mainstay in the treatment of chronic hepatitis C (CHC). We aimed to evaluate the efficacy of this treatment in patients with CHC, while considering new approaches.

Methods: A total of 323 patients with CHC underwent PEG-IFN and ribavirin combination treatment from the 3 centers (2 in Ordu and 1 in Samsun provinces) in Middle Black Sea region between the years of 2003-2013.

Results: Of the patients, 208 (67%) were female and had a mean age 54 ± 10 years (median: 54; 19-70). Genotyping was performed in 163 patients, and 161 patients (98.8%) revealed genotype 1. Sustained virologic response (SVR) and the end of treatment response rates ere 58.3% and 75.6%, respectively. In patients with rapid virological response, the SVR rate was 85.1%, whereas in patients with a HCV RNA level less than 800,000 IU/ml, the SVR rate was 71.2%. The SVR rates were found to be higher in patients who developed hypothyroidism, which was statistically significant (p = 0.03). The most frequent side effect was anemia, followed by thrombocytopenia, fatigue, and loss of appetite.

Conclusion: Presently, PEG-IFN/ribavirin is still an option in the treatment of certain patient populations even after the consideration of newer treatment methods. J Microbiol Infect Dis 2015;5(4): 151-155

Key words: Pegylated interferon, ribavirin, therapy, hepatitis C

References

  • Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014;7;20:9633-9652.
  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of
  • hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011;31 Suppl 2:30-60.
  • McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593.
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virüs infection. N Engl J Med 2002;347:975-982.
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial. Lancet 2001;358:958-965.
  • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group Peginterferon-alpha 2a and ribavirin
  • combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
  • Conjeevaram HS, Fried MW, Jeffers LJ, et al. Virahep-C Study
  • Group Peginterferon and ribavirin treatment in African American
  • and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477.
  • Jacobson IM, Brown RS Jr, McCone J, et al. WIN-R Study Group Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virüs genotype 1. Hepatology 2007;46:982-990.
  • Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection.World J Gastroenterol 2008;14:3416-3420.
  • Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-1359.
  • Berg T, Weich V, Teuber G, et al. Individualized treatment
  • strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-377.
  • Mauss S, Berg T, Rockstroh J Sarrazin C, Wedemeyer H. Short Guide to Hepatitis C 2013 edition.
  • Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment
  • with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
  • Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 suppl 1):237–244.
  • Mauss S, Hueppe D, Zehnter E, et al. Thyroid dysfunctioninduced
  • by Peginterferon-alfa-2b/ribavirin (Peg2b/RBV) is a favorable predictor of SVR in patients with HCV genotype 1but not genotype 2/3 infection. APASL Liver Week 6th-10th June 2013. Singapore p288.

-

Year 2015, Volume: 5 Issue: 4, 151 - 155, 06.02.2016
https://doi.org/10.5799/ahinjs.02.2015.04.0196

Abstract

-

References

  • Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014;7;20:9633-9652.
  • Cornberg M, Razavi HA, Alberti A, et al. A systematic review of
  • hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011;31 Suppl 2:30-60.
  • McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593.
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virüs infection. N Engl J Med 2002;347:975-982.
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomized trial. Lancet 2001;358:958-965.
  • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group Peginterferon-alpha 2a and ribavirin
  • combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
  • Conjeevaram HS, Fried MW, Jeffers LJ, et al. Virahep-C Study
  • Group Peginterferon and ribavirin treatment in African American
  • and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477.
  • Jacobson IM, Brown RS Jr, McCone J, et al. WIN-R Study Group Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virüs genotype 1. Hepatology 2007;46:982-990.
  • Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection.World J Gastroenterol 2008;14:3416-3420.
  • Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-1359.
  • Berg T, Weich V, Teuber G, et al. Individualized treatment
  • strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-377.
  • Mauss S, Berg T, Rockstroh J Sarrazin C, Wedemeyer H. Short Guide to Hepatitis C 2013 edition.
  • Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment
  • with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
  • Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 suppl 1):237–244.
  • Mauss S, Hueppe D, Zehnter E, et al. Thyroid dysfunctioninduced
  • by Peginterferon-alfa-2b/ribavirin (Peg2b/RBV) is a favorable predictor of SVR in patients with HCV genotype 1but not genotype 2/3 infection. APASL Liver Week 6th-10th June 2013. Singapore p288.
There are 22 citations in total.

Details

Primary Language English
Journal Section Brief Report
Authors

Aynur Atilla

Emel Duyar This is me

Fatih Bostancı This is me

S. Sırrı Kılıç This is me

Publication Date February 6, 2016
Published in Issue Year 2015 Volume: 5 Issue: 4

Cite

APA Atilla, A., Duyar, E., Bostancı, F., Kılıç, S. S. (2016). Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases. Journal of Microbiology and Infectious Diseases, 5(4), 151-155. https://doi.org/10.5799/ahinjs.02.2015.04.0196
AMA Atilla A, Duyar E, Bostancı F, Kılıç SS. Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases. J Microbil Infect Dis. February 2016;5(4):151-155. doi:10.5799/ahinjs.02.2015.04.0196
Chicago Atilla, Aynur, Emel Duyar, Fatih Bostancı, and S. Sırrı Kılıç. “Pegylated Interferon/Ribavirin Dual Therapy in Patients With Chronic Hepatitis C: Results of 323 Cases”. Journal of Microbiology and Infectious Diseases 5, no. 4 (February 2016): 151-55. https://doi.org/10.5799/ahinjs.02.2015.04.0196.
EndNote Atilla A, Duyar E, Bostancı F, Kılıç SS (February 1, 2016) Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases. Journal of Microbiology and Infectious Diseases 5 4 151–155.
IEEE A. Atilla, E. Duyar, F. Bostancı, and S. S. Kılıç, “Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases”, J Microbil Infect Dis, vol. 5, no. 4, pp. 151–155, 2016, doi: 10.5799/ahinjs.02.2015.04.0196.
ISNAD Atilla, Aynur et al. “Pegylated Interferon/Ribavirin Dual Therapy in Patients With Chronic Hepatitis C: Results of 323 Cases”. Journal of Microbiology and Infectious Diseases 5/4 (February 2016), 151-155. https://doi.org/10.5799/ahinjs.02.2015.04.0196.
JAMA Atilla A, Duyar E, Bostancı F, Kılıç SS. Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases. J Microbil Infect Dis. 2016;5:151–155.
MLA Atilla, Aynur et al. “Pegylated Interferon/Ribavirin Dual Therapy in Patients With Chronic Hepatitis C: Results of 323 Cases”. Journal of Microbiology and Infectious Diseases, vol. 5, no. 4, 2016, pp. 151-5, doi:10.5799/ahinjs.02.2015.04.0196.
Vancouver Atilla A, Duyar E, Bostancı F, Kılıç SS. Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases. J Microbil Infect Dis. 2016;5(4):151-5.